Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Department of Internal Medicine, Division of Nephrology, School of Medicine, University of Ioannina, Ioannina, Greece.
Crit Rev Oncol Hematol. 2020 Jul;151:102979. doi: 10.1016/j.critrevonc.2020.102979. Epub 2020 May 7.
Treatment of oncologic patients has progressed greatly the last few years with the development of immune checkpoint inhibitors (ICPIs). These drugs are associated with the immune system and, thus, may cause side effects of immune origin, the so called immune related adverse events (irAEs). Immune related AEs may actually affect all organs and systems and frequently resemble clinical entities commonly encountered in clinical practice. As ICPIs have improved both quality of life and life expectancy, clinicians of various specialties may need to deal with irAEs in their everyday practice. Therefore, they should be able to recognize them timely and treat them accordingly. Herein, we review the pathophysiology, clinical manifestations and treatment of irAEs.
近年来，随着免疫检查点抑制剂（ICPI）的发展，肿瘤患者的治疗取得了很大进展。这些药物与免疫系统相关，因此可能会引起免疫相关的不良反应（irAEs）。免疫相关 AEs 实际上可能影响所有器官和系统，并且经常类似于临床实践中常见的临床实体。由于 ICPIs 提高了生活质量和预期寿命，因此各个专业的临床医生在日常实践中可能需要处理 irAEs。因此，他们应该能够及时识别它们并进行相应的治疗。在此，我们回顾了 irAEs 的发病机制、临床表现和治疗。
